Top Ten Videos to watch

Hillary Clinton Meets With DC Mayor And DC Representative At Coffee Shop
crime scene
Vote
Studio Portrait of Two Young Women Back to Back, One With a Tattoo
Mamie Till and Emmett Till
GOP Redistricting Plot To Unseat Rep. Corrine Brown Exposed
Protests Break Out In Charlotte After Police Shooting
'Keep the Vote Alive!' March Commemorates Civil Rights Act
White man shooting
Gun Violence Continues To Plague Chicago, Over 1,000 Shootings For Year To Date
HS Football
Gun Violence Continues To Plague Chicago, Over 1,000 Shootings For Year To Date
Police Line
US-POLITICS-OBAMA
2016 Republican National Convention
44th NAACP Image Awards - Show
MD Primary
Premiere Of OWN's 'Queen Sugar' - Arrivals
Democratic National Convention
US-VOTE-REPUBLICANS-TRUMP
Los Angeles Rams v San Francisco 49ers
US-POLICE-RACISM-UNREST
Protesters Demonstrate Against Donald Trump's Visit To Flint Michigan
President Obama Speaks On The Economy In Brady Press Briefing Room
Lil Wayne
Construction Continues On The National Museum of African American History To Open In 2016
Preacher Preaching the Gospel
Hillary Clinton Campaigns In Louisville, Kentucky
Miami Dolphins v Seattle Seahawks
US-VOTE-DEMOCRATS-CONVENTION
Leave a comment

European Union regulators approved Merck & Co.’s hepatitis C drug Victrelis, the company said Monday.

The ruling allows Merck to market Victrelis in all 27 European Union countries. Victrelis is a pill taken three times per day, and it blocks an enzyme that helps the hepatitis C virus reproduce.

It was approved for use in combination with standard drugs in patients who are untreated or have failed on other treatments. Victrelis is given with Roche’s injected hepatitis C drug Pegasys and ribavirin pills.

U.S. regulators approved Victrelis on May 13.

Shares of Merck dropped 60 cents, or 1.7 percent, to $35.33 in afternoon trading amid a broad market retreat.

Also On News One:
comments – Add Yours